Search alternatives:
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
Showing 1,101 - 1,120 results of 110,061 for search '(( a point decrease ) OR ( 5 ((((we decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.72s Refine Results
  1. 1101
    The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages.

    The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages. by Manuela Mally (348810)

    Published 2013
    Save to List
    Saved in:
  2. 1102
    Compatible pollen triggers a decrease in S-RNase transcript levels by a post-transcriptional mechanism.

    Compatible pollen triggers a decrease in S-RNase transcript levels by a post-transcriptional mechanism. by Bolin Liu (59887)

    Published 2009
    Save to List
    Saved in:
  3. 1103
    Correlates of osteogenic differentiation.

    Correlates of osteogenic differentiation. by Fabian Westhauser (5314436)

    Published 2019
    Save to List
    Saved in:
  4. 1104
    A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner.

    A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner. by Shiva Mansouri (2838086)

    Published 2016
    Save to List
    Saved in:
  5. 1105
    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells.

    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

    Published 2014
    Save to List
    Saved in:
  6. 1106
    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells.

    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

    Published 2014
    Save to List
    Saved in:
  7. 1107
    Resveratrol decreases CYP17A1 and CYP21A2 protein expression.

    Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

    Published 2017
    “…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …”
    Save to List
    Saved in:
  8. 1108
    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells.

    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

    Published 2013
    Save to List
    Saved in:
  9. 1109
    An outline of our methodology.

    An outline of our methodology. by Krishna Bathina (12883820)

    Published 2022
    Save to List
    Saved in:
  10. 1110
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 1111
    CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i><sup><i>ECKO</i></sup> mice and lesions in the retina of <i>Ccm2</i><sup><i>ECKO</i></sup> mice.

    CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i><sup><i>ECKO</i></sup> mice and lesions in the retina of <i>Ccm2</i><sup><i>ECKO</i></sup> mice. by Jia Li (160557)

    Published 2020
    Save to List
    Saved in:
  12. 1112
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 1113
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 1114
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1115
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 1116
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 1117
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 1118
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 1119
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 1120
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: